Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer
暂无分享,去创建一个
C. Print | C. Blenkiron | S. Grimmond | J. Windsor | A. MacCormick | S. Connor | N. Knowlton | P. Tsai | B. Lawrence | P. Reid | Adam Bartlett | M. Findlay | S. Fitzgerald | K. Henare | V. Fan | K. Parker | P. Shields | T. Robb | M. Yeong | N. Kramer | S. James | M. Black | Nooriyah Poonawala | P. Yap | E. Coats | B. Woodhouse | R. Ramsaroop | M. Yozu | B. Robinson | J. Koea | P. Johnston | R. Carroll | H. Morrin | M. Elston | C. Jackson | R. Babor | D. Damianovich | S. Grimmond | P. Johnston | Christopher Jackson | A. MacCormick | J. Windsor | P. Tsai | Patrick Yap
[1] C. Larsson,et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma , 1988, Nature.
[2] James Allan,et al. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. , 1999, Mutagenesis.
[3] P. Beck‐Peccoz,et al. Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma. , 2003, The Journal of clinical endocrinology and metabolism.
[4] T. Speed,et al. Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.
[5] Benjamin M. Bolstad,et al. affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..
[6] S. Gerson. MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.
[7] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[8] Jeffrey T. Chang,et al. GATHER: a systems approach to interpreting genomic signatures , 2006, Bioinform..
[9] A. Rashid,et al. Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis. , 2007, Endocrine-related cancer.
[10] Hadley Wickham,et al. ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .
[11] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[12] Jeffrey W. Clark,et al. O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors , 2008 .
[13] F. Bosman,et al. WHO Classification of Tumours of the Digestive System , 2010 .
[14] S. Beghelli,et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. , 2010, Endocrine-related cancer.
[15] C. Croce,et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Michael A. Choti,et al. DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.
[17] Marcel Martin. Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .
[18] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[19] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[20] D. Coppola,et al. First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas , 2011, Cancer.
[21] Gonçalo R. Abecasis,et al. The variant call format and VCFtools , 2011, Bioinform..
[22] Ben Lawrence,et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. , 2011, Endocrinology and metabolism clinics of North America.
[23] E. D. de Vries,et al. Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[24] S. Salzberg,et al. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts , 2011, Genome Biology.
[25] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[26] R. McLendon,et al. Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.
[27] Thomas Zichner,et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..
[28] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[29] J. Chabot,et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience , 2013, Cancer Chemotherapy and Pharmacology.
[30] Wendy S. W. Wong,et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..
[31] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[32] Hiromitsu Araki,et al. GeneSetDB: A comprehensive meta-database, statistical and visualisation framework for gene set analysis , 2012, FEBS open bio.
[33] S. Elledge,et al. Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome , 2013, Cell.
[34] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[35] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[36] B. Ebert,et al. Deletion 5q MDS: molecular and therapeutic implications. , 2013, Best practice & research. Clinical haematology.
[37] Jiaqian Wang,et al. Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1 , 2013, Nature Communications.
[38] Heng Li. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.
[39] S. Kreth,et al. Personalized treatment strategies in glioblastoma: MGMT promoter methylation status , 2013, OncoTargets and therapy.
[40] Jianmin Wu,et al. Somatic Point Mutation Calling in Low Cellularity Tumors , 2013, PloS one.
[41] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..
[42] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[43] Anushya Muruganujan,et al. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees , 2012, Nucleic Acids Res..
[44] S. Halgamuge,et al. Inferring copy number and genotype in tumour exome data , 2014, BMC Genomics.
[45] E. Speel,et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. , 2014, Gastroenterology.
[46] Thomas Lengauer,et al. Comprehensive Analysis of DNA Methylation Data with RnBeads , 2014, Nature Methods.
[47] Sohrab P. Shah,et al. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data , 2014, Genome research.
[48] Andreas Krämer,et al. Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..
[49] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[50] C. Romualdi,et al. Prognostic Relevance of Aberrant DNA Methylation in G1 and G2 Pancreatic Neuroendocrine Tumors , 2014, Neuroendocrinology.
[51] Andrew E. Teschendorff,et al. ChAMP: 450k Chip Analysis Methylation Pipeline , 2014, Bioinform..
[52] Rafael A. Irizarry,et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..
[53] A. Amon,et al. Short- and long-term effects of chromosome mis-segregation and aneuploidy , 2015, Nature Reviews Molecular Cell Biology.
[54] D. Hanahan,et al. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. , 2015, Cancer discovery.
[55] Sabine Tejpar,et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[57] V. Paradis,et al. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors , 2015, Neuroendocrinology.
[58] Julian Gehring,et al. SomaticSignatures: inferring mutational signatures from single-nucleotide variants , 2014, bioRxiv.
[59] Rezvan Ehsani,et al. EpiFactors: a comprehensive database of human epigenetic factors and complexes , 2015, Database J. Biol. Databases Curation.
[60] A. Meeker,et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. , 2016, Endocrine-related cancer.
[61] E. Mardis,et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens , 2016, Genome Medicine.
[62] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[63] Xiaoyu Chen,et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications , 2016, Bioinform..
[64] Z. Storchová,et al. Effects of aneuploidy on gene expression: implications for cancer , 2016, The FEBS journal.
[65] Obi L. Griffith,et al. GenVisR: Genomic Visualizations in R , 2016, bioRxiv.
[66] Andrew J. Hill,et al. Analysis of protein-coding genetic variation in 60,706 humans , 2015, bioRxiv.
[67] V. Paradis,et al. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. , 2016, Endocrine-related cancer.
[68] Ignace Vergote,et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.
[69] Shivashankar H. Nagaraj,et al. Whole-genome landscape of pancreatic neuroendocrine tumours , 2017, Nature.
[70] T. Speed,et al. GRIDSS: sensitive and specific genomic rearrangement detection using positional de Bruijn graph assembly. , 2017, Genome research.
[71] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[72] M. Mahajan,et al. Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas , 2017, Nature Communications.
[73] M. Fiorentino,et al. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study , 2018, Endocrine.
[74] E. Raymond,et al. Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms , 2018, Neuroendocrinology.
[75] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.